Anti-DYRK1A antibody produced in rabbit

DYRK1A (dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A) is a highly conserved kinase, which is a member of the CMGC family of protein kinases. It is a serine/threonine kinase, which is a Drosophila minibrain gene homolog. This gene is localized to human chromosome 21, and is expressed in both nucleus and cytoplasm. It has a ubiquitous expression pattern, and shows predominant expression in hippocampus, cerebellum and olfactory bulb.

Dual specificity tyrosine-phosphorylation-regulated kinase 1A recombinant protein epitope signature tag (PrEST)

All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry.

The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies^® protocols and other useful information.

DYRK1A (dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A) is involved in the homeostasis of tissues, and in human development. This gene is up-regulated in Down syndrome (DS) patients, which is linked with changes in motor functions, osteoporosis, aberrations in retina etc. Mutations resulting in truncated protein are linked to retardation in general growth and severe primary microcephaly. Mutations in this gene are also associated with deregulation of pancreatic function, and progression of tumor. This gene is down-regulated in Alzheimer′s disease, and its plasma levels might be diagnostic marker for the same. It acts as a tumor suppressor in acute myeloid leukemia (AML), and its expression is suppressed in the same. It suppresses the proliferation of AML cells, by degrading c-Myc, and also influences chemoresistance in AML patients.

Prestige Antibodies^® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies^® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.

Every Prestige Antibody is tested in the following ways:

• IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
• Protein array of 364 human recombinant protein fragments.

Corresponding Antigen APREST73513

Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide

Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.